logo
Craving management workshops and peer-led support are helping French prisons reframe addiction as a healthcare issue.

Craving management workshops and peer-led support are helping French prisons reframe addiction as a healthcare issue.

Medscape16-06-2025
The most recent congress of the French association of healthcare professionals working in the prison service (ASPEP), held in Paris, revisited the issue of substance use disorders among incarcerated individuals.
For many years, drug use in prisons was met with ambiguity — or even outright denial — by authorities. The prison administration maintained the somewhat simplistic belief that because drug use is illegal, it could not exist in a system where the law is meant to prevail.
This perspective began to shift in the early 1980s, when concern over the transmission of HIV and hepatitis from injectable drug use prompted a more serious response. However, the focus at the time remained on controlling infectious disease risk rather than addressing addiction as a medical condition.
That era has since passed. Today, prison authorities — working alongside healthcare professionals — acknowledge the reality of both drug use and addiction within correctional settings.
A major step forward came in May 2024 with the publication of the first national statistical survey on substance use in French prisons: The ESSPRI study (Survey on Health and Substance Use in Prisons), led by the French Monitoring Centre for Drugs and Drug Addiction (OFDT). The study reflects a growing commitment among the medical community to objectively assess and address substance use behind bars.
The survey was conducted between April and June 2023 and included approximately 1000 inmates aged 18 years or older. It assessed their use of psychoactive substances. The results — revisited at the March ASPEP congress — revealed significant levels of substance use:
63% of inmates reported daily tobacco use (compared with 25% of adult men in the general population)
26% reported using cannabis (vs 3% outside prison)
14% had used other illicit substances (including cocaine, crack, MDMA, and heroin) since being incarcerated
Targeted Policy Recommendations
By contrast, alcohol use within French prisons appears relatively low: Only 16% of inmates reported drinking alcohol while incarcerated. However, this is likely due to limited availability rather than a voluntary choice to abstain.
Based on its findings, the OFDT identified three broad patterns of substance use among inmates:
One third — primarily younger inmates — regularly use both tobacco and cannabis.
One third use only tobacco.
One third — often older inmates — do not use any psychoactive substances.
The OFDT called for health policies that reflect these actual patterns of use. In particular, they recommended that prevention and treatment strategies within prisons focus more specifically on tobacco and cannabis, which are the most widely used substances.
Transition After Release
Across France, various initiatives have emerged to improve addiction care in correctional settings. However, program implementation remains fragmented, as most addiction services are organized independently by individual prison-based addiction treatment centers (known as CSAPAs). Despite this lack of coordination, some initiatives are particularly noteworthy.
At the Bois-d'Arcy remand center in Yvelines, for example, CSAPA staff have introduced 'release kits' to support continuity of care for inmates with substance use disorders as they transition back into the community. This post-release period is a time of heightened vulnerability, marked by unstable living conditions and an increased risk of high-risk behaviors. In fact, post-release mortality — primarily due to suicide or overdose — is 3.6 times higher than during incarceration.
The release kits, developed collaboratively with inmates and grounded in harm-reduction principles, are available in three versions tailored to individual needs:
Basic kit: Includes key information, such as emergency contact numbers and referral options for addiction specialists.
Kit for crack and cocaine users: Offers harm-reduction materials and substance-specific guidance to promote safer consumption practices.
Kit for individuals who inject drugs: Contains sterile injection equipment and a dose of naloxone for emergency overdose reversal.
Workshops to Address Craving
At Baumettes Prison in Marseille, France, the local CSAPA has developed a program focused on managing craving — the intense urge to use substances experienced by individuals with addiction.
Care is delivered through therapeutic workshops codesigned with inmates. These consist of four weekly group sessions facilitated by two healthcare professionals. Each group includes up to six participants and encourages open discussion of cravings and coping strategies, with a strong focus on shared experience and peer support.
'We explore how patients perceive their cravings and work to activate their psychosocial skills so they can draw on their own internal resources,' explained Camille Normandin, Elisa Carta, and Damien Mauillon during a presentation at the recent ASPEP congress.
The workshops provide education on the physiological mechanisms underlying craving, while also helping participants develop personalized relapse prevention strategies. Inmates are encouraged to identify their own high-risk situations and develop tailored solutions to avoid giving in to urges.
While pharmacologic substitution therapies are addressed, 'the real focus is on empowering inmates to draw on their own experiences and insights,' emphasized the CSAPA team from Baumettes.
The ASPEP congress also served as a platform for healthcare professionals working in the prison system to call for better coordination of addiction services and, importantly, for more transparent and stable funding — which they described as inconsistent and difficult to track across facilities.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast
Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast

Yahoo

timea day ago

  • Yahoo

Cat dementia is similar to human Alzheimer's disease ...Tech & Science Daily podcast

Listen here on your chosen podcast platform. Cats develop dementia similarly to humans with Alzheimer's disease. Scientists hope their findings lead to new treatments for both humans and our feline friends. For more, we spoke to the lead author, Dr Robert McGeachan, at the University of Edinburgh's Royal School of Veterinary Studies. A swarm of jellyfish forced the shutdown of France's largest nuclear power plant, Gravelines. But how unusual is this event? And, Reddit blocks the Internet Archive's Wayback Machine from archiving large portions of its site. Also in this episode: -How blowing through a conch shell could alleviate the symptoms of obstructive sleep apnoea -Lola Young urges Keir Starmer to block Rosebank oil and gas development projects -Natalie the Nerd builds a transparent GameBoy Colour

Morgan Baine, beloved Nashville substance abuse treatment executive, dies at 32: 'She spoke truth with compassion'
Morgan Baine, beloved Nashville substance abuse treatment executive, dies at 32: 'She spoke truth with compassion'

Yahoo

time3 days ago

  • Yahoo

Morgan Baine, beloved Nashville substance abuse treatment executive, dies at 32: 'She spoke truth with compassion'

Hundreds in Nashville's substance abuse recovery community are grieving the sudden death of 32-year-old Morgan Baine, who helped launch treatment programs and advocated for women facing addiction for the last five years. Baine — program director for nonprofit Healing Housing residential recovery for women and owner of her own 10-bed women's sober living house — died Aug. 12 at her home. Friends and colleagues said Baine's passion to serve women healing from active addiction stemmed in part from finding recovery herself in a sober living house. 'She loved big, and she believed in the women of Healing Housing with everything she had," said Brooke Stephens, a coworker and friend. "She spoke truth with compassion, always urging us to see our own strength, even when we could not see it ourselves. Her kindness, wisdom, and fierce belief in our worth will forever be part of our home and our hearts.' Baine, a one-time student of Franklin High School in Franklin, Tennessee, started working at Healing Housing in 2020 as an executive assistant and was named program director there in October 2023. She opened her own sober living house, Phoenix Recovery, in December 2023. Healing Housing executive director Tracey Levine called Baine "the heartbeat" of the nonprofit. "Morgan leaves behind a legacy of resilience, love, and transformation that will continue to inspire all who knew her," Levine said. Friends also knew Baine as a rabid Nashville Predators fan who went to many home games for the past several seasons. Baine is survived by her 13-year-old son, James, and her fiancé, Logan Terry, who also works in substance abuse recovery. Baine and her son loved live music and "would head out to a festival at a moment's notice," her mother, Barbra Bedwell, said. As a girl, Baine enjoyed traveling with her grandparents and reading books under the covers after her bedtime, her mom said. Other survivors include her parents, Carl and Barbra Bedwell of College Grove, Tennessee; her brother Hunter Bedwell of Tampa, Florida; her brother David Baine of Germantown, Tennessee; her sister, Rachel Helm (John), of Eureka Springs, Arkansas; and her grandfather J. Paul Price of Germantown, Tennessee. Visitation is set for noon Aug. 15 at Brentwood United Methodist Church in Brentwood, Tennessee, with a celebration of life following at 1 p.m. The family is requesting donations be made to Healing Housing online at Reach Brad Schmitt at brad@ This article originally appeared on Nashville Tennessean: Morgan Baine, Nashville substance abuse treatment exec dies at 32

GLP-1 Receptor Agonists Improve HS in Patients With Obesity
GLP-1 Receptor Agonists Improve HS in Patients With Obesity

Medscape

time3 days ago

  • Medscape

GLP-1 Receptor Agonists Improve HS in Patients With Obesity

TOPLINE: Investigators reported that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were associated with significant improvements in clinical severity, patient-reported outcomes, and weight in patients with hidradenitis suppurativa (HS) and obesity. METHODOLOGY: The retrospective multicenter cohort study evaluated 66 adults (median age, 46 years; 58% women) with HS who received semaglutide, dulaglutide, or liraglutide for at least 3 months, using data from eight French hospitals, between 2017 and 2024. Their median BMI was 39.4, and 86% of patients had diabetes; 45%, 32%, and 23% of patients had Hurley stages I, II, and III disease, respectively. Outcomes included HS-Physician's Global Assessment (HS-PGA), flare frequency, Numerical Rating Scale (NRS)-Pain, NRS-Suppuration, Dermatology Life Quality Index (DLQI), and BMI at 6 months. Median follow-up was 18.5 months. TAKEAWAY: At 6 months, 54% of patients had achieved at least one-point reduction in HS-PGA and 12% of patients demonstrated at least two-point reduction; flares were reduced in 60% patients. NRS-Pain scores decreased in 52% of patients, NRS-Suppuration scores decreased in 53% patients, and improved quality of life, based on DLQI scores, was observed in 50% patients at 6 months. Among 34 patients with stable HS treatment, all outcome measures showed statistically significant improvements at 6 months (P < .001). Median BMI decreased from 39.4 to 37.2 at 6 months. IN PRACTICE: 'GLP-1 RAs offer promise for patients with HS and obesity and potentially for patients without obesity through immunological effects,' the study authors wrote. 'Randomized clinical trials are warranted to confirm the role of GLP-1 RAs in HS management,' they added. SOURCE: The study was led by Louise Gouvrion, MD, Department of Dermatology, Rennes University Hospital in Rennes, France, and was published online on August 13 in JAMA Dermatology. LIMITATIONS: The retrospective design, concurrent use of diverse HS therapies, potential selection bias, and absence of glycemic and inflammatory biomarker data limit causal inference. DISCLOSURES: The authors did not disclose any funding information. Several authors reported receiving personal fees, conference invitations, nonfinancial support from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Lilly, Janssen, LEO Pharma, MSD, Novartis, UCB, and others. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store